Results 131 to 140 of about 1,744 (184)

ORItavancin as a therapeutic regimen for Cardiac Implantable Electronic Devices infections with multidrug-resistant Gram-positive cocci (ORI-4-CIEDi) pilot study: rationale and design. [PDF]

Cardiol J
Łoboda D, Swolana D, Joniec M, Gładysz-Wańha S, Gibiński M, Simionescu K, Piłat E, Gołba KS, Wojtyczka RD, Wilczyński S, Sarecka-Hujar B.   +10 more
europepmc   +1 more source

Comparative Analysis of Adverse Drug Reactions Between Oritavancin Diphosphate and Oritavancin-HPβCD Using FAERS Data. [PDF]

Hosp Pharm
Castellana E, Chiappetta MR.
europepmc   +1 more source

Off-label use of oritavancin: a case series on clinical effectiveness, bed-day savings and cost benefits. [PDF]

JAC Antimicrob Resist
Patel A, Walden A, Iyer S, Okoibhole A.
europepmc   +1 more source

A Comparative Review of the Pharmacology of Dalbavancin and Oritavancin for Gram-Positive Infections: Birds of a Feather or Apples and Oranges? [PDF]

Infect Dis Ther
Hussein M, Barclay J, Baker M, Wu Y, Thombare VJ, Patil N, Murthy AB, Sharma R, Rao GG, Blaskovich MAT, Li J, Velkov T.   +11 more
europepmc   +1 more source

265Hepatic Safety in Acute Bacterial Skin and Skin Structure Infection (ABSSSI) Patients Receiving Tedizolid (TZD) vs Linezolid (LZD) [PDF]

Open Forum Infectious Diseases, 2014
Catherine Hardalo, Edward Fang, Carisa De Anda, Sonia Minassian, Philippe Prokocimer   +4 more
openaire   +1 more source

Impact of obesity on clinical outcomes in patients treated with ceftobiprole: results from Phase 3 clinical trials. [PDF]

J Antimicrob Chemother
Holland TL, Shorr AF, Overcash JS, Engelhardt M, Jones M, Ionescu D, Litherland K, Saulay M, Fowler VG.   +8 more
europepmc   +1 more source

Correction: Molecular resistance mechanisms to newly approved antibiotics (2017-2025) in WHO priority pathogens. [PDF]

Front Microbiol
Frontiers Production Office.
europepmc   +1 more source

A Phase 3 Study of the Safety and Efficacy of Tedizolid Phosphate in Patients <12 Years of Age With Acute Bacterial Skin and Skin Structure Infections. [PDF]

Pediatr Infect Dis J
Mngqibisa R, Fofanov O, Grazioso CF, Melgar Toledo M, Boddicker M, Broyde N, Koseoglu S, Romero L, Stevens M, Sears P.   +9 more
europepmc   +1 more source

Experience of use of dalbavancin for the treatment of unlicensed indications in a UK tertiary infectious diseases setting. [PDF]

Infection
Darlow CA, Parsons J, Lucy D, Li A, Ratcliffe L, Todd S, Wong N.   +6 more
europepmc   +1 more source

Are Oritavancin and Dalbavancin More Cost Effective for Outpatient Parenteral Antimicrobial Therapy at a Veterans Affairs Medical Center? [PDF]

Fed Pract
Hanks D, Jodlowski TZ, Madaras-Kelly K, Diaz J, Vietri N.   +4 more
europepmc   +1 more source